The Slippery Slope of Off-Label Marketing

Interesting article from Fierce Biotech regarding the recent Department of Justice subpoena related to Merck’s Temodar.

As social media continues to evolve and become such an integral way of life for so many people, the FDA will be challenged to define the way life science companies can use this necessary form of communication without exploiting it. Certainly, the use of marketing off-label through the use of social media sites like Facebook and Twitter will continue to happen, and regulating this will be difficult for a financially strapped federal organization like the FDA. In many ways, the future use will have to be self regulated by responsible parties within the industry, such as regional life science organizations, advocates like BIO, and the big pharma players that have so much to lose if this goes wrong.

Leave a Reply

Your email address will not be published. Required fields are marked *